Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

New Interactive Biosimilar Tool Can Help Educate Providers and Patients

December 13th 2023

By Skylar Jeremias

Article

Biosim.care is a new interactive education tool that can help patients, caregivers, and providers navigate decision-making and treatment conversations for multiple disease states.

Eye on Pharma: Hadlima Interchangeability; CHMP Green Lights Ustekinumab; Biosimilars Forum Supports Draft Legislation

December 12th 2023

By Skylar Jeremias

Article

The FDA agreed to review an application for Hadlima (adalimumab biosimilar) to be granted interchangeability; The European Union’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for an ustekinumab biosimilar; the Biosimilars Forum expressed support for a Senate Finance Committee’s draft legislation promoting biosimilars.

Study Shows Similar Efficacy, Drug Survival Rates for Etanercept Biosimilar vs Originator in RA

December 11th 2023

By Cameron Santoro

Article

A national study on patients with rheumatoid arthritis (RA) compares the disease activity and drug survival rate between an etanercept biosimilar and the originator (Enbrel).

Cencora's Brian Biehn Forecasts Big Changes for the US Biosimilar Space

December 10th 2023

By Skylar Jeremias

Video

Brian Biehn, senior director of biosimilar commercialization at Cencora, makes predictions for how big regulatory approvals in 2023 will shape the biosimilar space going forward.

Factors Physicians Should Consider When Selecting an Adalimumab Biosimilar

December 9th 2023

By Deana Ferreri, PhD

Article

A review article discussed the characteristics of the available adalimumab biosimilars to help clinicians navigate the various treatment options with their patients.

The Top 5 Biosimilar Articles for the Week of December 4

December 8th 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 4, 2023.

Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models

December 7th 2023

By Laura Joszt, MA

Article

A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.

Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab

December 6th 2023

By Skylar Jeremias

Article

Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.

Adalimumab Biosimilar GP2017 Shows Similar Safety, Efficacy to Originator in Patients With IBD

December 5th 2023

By Cameron Santoro

Article

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.

BioRationality: Efficacy Testing and Interchangeability of Biosimilar Remains a Dogma for Most

December 4th 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, comments on a poll he conducted revealing that many are still hesitant to remove clinical efficacy study requirements for biosimilars in his latest column.